Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call Transcript

Jack Phillips: Yes. Thank you, everyone, and thanks for the time today. In summary, I’d like to just highlight a few things. First of all, we have made significant progress on our Wave program. This is our innovative technology that will allow us to not only tap into the rapid susceptibility market for PBC, but go well beyond that with isolate testing as well, $130 million test market. Customers and industry leaders continue to confirm Wave. The Wave system is a game-changing solution for all antibiotic testing, not just PBC. And over the next quarters, we will be providing much more data moving closer to a successful FDA submission sometime next year. Secondly, the clinical trials for Arc remain on track and performance data is looking quite good, and we anticipate a successful FDA submission and approval — submission in the coming months and approval after that.

And then finally, as I talked today, we’ll continue to make progress commercially with our BD partnership. It’s a good one. And by incorporating Pheno and Arc into their bloodstream infection, it’s really a winning total solution for bloodstream infections. On behalf of the entire management team, I’d like to thank you for your continued support and interest in Accelerate Diagnostics. Thank you again, and have a wonderful day.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.